Shifting the paradigm in autoimmune disease, tumor necrosis factor (TNF)-α inhibitors have taken root as major treatment option not only for rheumatoid arthritis, but also for other various areas including ankylsoing spondylitis, psoriasis, and psoriatic arthritis.

Regardless, there are still patients struggling with unmet needs as they fail to control the diseases with TNF-α inhibitors. As a result of many pharmaceutical companies jumping into developing alternatives of TNF-α inhibitors, other options like Janus kinase (JAK) inhibitor and interleukin (IL) inhibitors have emerged.

Considering the change in treatment scene, Pfizer is a key player in the autoimmune disease area. The